ArticleLiver cancer2025

Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab.

Jaekyung Cheon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.